Literature DB >> 17384125

Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide.

E Büssemaker1, Frank Pistrosch, Sarah Förster, Kay Herbrig, Peter Gross, Jens Passauer, Ralf P Brandes.   

Abstract

Our objective was to determine the role of the Rho-associated kinase (ROK) for the regulation of FBF (FBF) and to unmask a potential role of ROK for the regulation of endothelium-derived nitric oxide (NO). Moreover, the effect of fasudil on the constrictor response to endothelin-1 was recorded. Regarding background, phosphorylation of the myosin light chain (MLC) determines the calcium sensitivity of the contractile apparatus. MLC phosphorylation depends on the activity of the MLC kinase and the MLC phosphatase. The latter enzyme is inhibited through phosphorylation by ROK. ROK has been suggested to inhibit NO generation, possibly via the inhibition of the Akt pathway. In this study, the effect of intra-arterial infusion of the ROK inhibitor fasudil on FBF in 12 healthy volunteers was examined by venous occlusion plethysmography. To unmask the role of NO, fasudil was infused during NO clamp. As a result, fasudil markedly increased FBF in a dose-dependent manner from 2.34 +/- 0.21 to 6.96 +/- 0.93 ml/100 ml forearm volume at 80 mug/min (P < 0.001). At 1,600 mug/min, fasudil reduced systolic, diastolic, and mean arterial pressure while increasing heart rate. Fasudil abolished the vasoconstrictor effect of endothelin-1. The vascular response to fasudil (80 mumol/min) was blunted during NO clamp (104 +/- 18% vs. 244 +/- 48% for NO clamp + fasudil vs. fasudil alone; data as ratio between infused and noninfused arm with baseline = 0%, P < 0.05). In conclusion, 1) basal peripheral and systemic vascular tone depends on ROK; 2) a significant portion of fasudil-induced vasodilation is mediated by NO, suggesting that vascular bioavailable NO is negatively regulated by ROK; and 3) the constrictor response to endothelin involves the activation of ROK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384125     DOI: 10.1152/ajpheart.00770.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  17 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.

Authors:  Michie Toba; Abdallah Alzoubi; Kealan O'Neill; Kohtaro Abe; Takeo Urakami; Masanobu Komatsu; Diego Alvarez; Tero A H Järvinen; David Mann; Erkki Ruoslahti; Ivan F McMurtry; Masahiko Oka
Journal:  Am J Pathol       Date:  2014-01-06       Impact factor: 4.307

3.  Reduced Peripheral Blood Mononuclear Cell ROCK1 and ROCK2 Levels in Obstructive Sleep Apnea Syndrome.

Authors:  Şenay Aydin; Cengiz Özdemir; Cem Ismail Küçükali; Sinem Nedime Sökücü; Murat Giriş; Uğur Akcan; Erdem Tüzün
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.

Authors:  Francesca Schinzari; Manfredi Tesauro; Valentina Rovella; Nicola Di Daniele; Paolo Gentileschi; Nadia Mores; Umberto Campia; Carmine Cardillo
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-24       Impact factor: 4.310

5.  Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Nancy Tseng; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

6.  Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia.

Authors:  C R de Andrade; P F Leite; A C Montezano; D A Casolari; A Yogi; R C Tostes; R Haddad; M N Eberlin; F R M Laurindo; H P de Souza; F M A Corrêa; A M de Oliveira
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

7.  Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease.

Authors:  Ming Dong; Xin Jiang; James K Liao; Bryan P Yan
Journal:  Clin Cardiol       Date:  2013-03-28       Impact factor: 2.882

8.  Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension.

Authors:  Hoanglan Nguyen; Valorie L Chiasson; Piyali Chatterjee; Shelley E Kopriva; Kristina J Young; Brett M Mitchell
Journal:  Cardiovasc Res       Date:  2012-12-21       Impact factor: 10.787

Review 9.  Challenges, priorities and novel therapies for hypoxemic respiratory failure and pulmonary hypertension in the neonate.

Authors:  J L Aschner; J Gien; N Ambalavanan; J P Kinsella; G G Konduri; S Lakshminrusimha; O D Saugstad; R H Steinhorn
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

10.  Role of Rho-kinase in mediating contraction of chicken embryo femoral arteries.

Authors:  Bea Zoer; Carlos E Blanco; Eduardo Villamor
Journal:  J Comp Physiol B       Date:  2010-03       Impact factor: 2.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.